SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors discuss the company's launch schedule and communication strategy following recent delays, with many expressing frustration over missed deadlines. The community is actively debating the potential impact of these delays on the stock price and the company's credibility, while some remain optimistic about the long-term potential of ASTS's technology and market opportunity. Bullish investors emphasize upcoming catalysts including launches and the potential for a market correction, but bearish investors believe current conditions such as missed deadlines make the stock unfavorable.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

AAPL is trending as the stock flirts with all-time highs, fueled by positive sentiment around holiday iPhone sales and potential shifts in AI strategy with a new VP of AI. Community discussions revolve around whether the stock is overvalued and if it can break $280, with some eyeing put positions as a hedge. Analysts are weighing in with price targets, while the broader market watches to see if Apple can continue to carry the market.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending following raised guidance and positive analyst target hikes after recent earnings, with community members discussing potential price movements and options strategies. The company's growth, particularly in its Atlas cloud database service, and its positioning in the AI space are key talking points. Some traders express caution regarding the valuation, while others remain bullish, anticipating further upside.

Fly-E Group, Inc. is an electric vehicle company, which engages in designing, installing, and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the brand Fly E-Bike. Its products include electric-scooter, e-bikes, parts, and accessories. The company was founded by Zhou Ou in 2018 and is headquartered in Flushing, NY.

Fly-E Group Inc.

Fly-E Group Inc

FLYE is experiencing significant volatility, with community members pointing to high short interest and a potential short squeeze as catalysts. Discussions revolve around risk management, with some cautioning against pump-and-dump schemes and others eyeing quick profits. The stock's past price swings and recent trading halts contribute to the heightened speculation.

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Janux Therapeutics Inc

JANX is trending due to a significant after-hours drop following the release of interim Phase 1 data for its drug candidate, JANX007, despite some community members viewing the data as positive. The community is debating the severity of the data and whether the selloff is an overreaction or a realistic assessment of the results. Broader discussions include buyout speculation and comparisons to other companies with similar T-cell masker programs.

Ambitions Enterprise Management Co. LLC operates as a travel agency. It provides event planning and management services. The firm also offers transportation, accommodations, meals, and guided tours or activities under convenient packages. The company was founded on October 26, 2023 and is headquartered in Dubai, United Arab Emirates.

Ambitions Enterprise Management Co LLC - Ordinary Shares - Class A

Ambitions Enterprise Management Co LLC

AHMA is trending due to its low float and massive gains, drawing comparisons to past runners like $SMX. Community chatter focuses on its potential for a short squeeze and continued upward momentum, with some eyeing price targets of $30-$50. The stock's volatility and recent IPO status are also key points of discussion.

What is Tron? Tron's mission is to build a truly decentralized internet and aims to be the largest blockchain-based operating system in the world, known as the TRON protocol. The TRON protocol will offer high scalability, high availability, and high throughput computing to serve decentralized applications via smart contracts. Ethereum EVM-based smart contracts will be compatible and deployable on the TRON network as such Solidity developers do not have to rewrite their applications.  Why Tron? Since TRON protocol does not rely on proof of work or mining, instead governed by nodes located around the world, it is decentralized while providing high throughput for transactions on the blockchain. This is suitable for dapps that require high speed transactions especially games. There are a number of tokens already issued on the TRON network and the decentralized exchanges TRX.market has launched.  On July 24th 2018, TRON acquired BitTorrent, one of the largest P2P file sharing protocol. As a result of the acquisition, BitTorrent Token (BTT) was launched as the cryptocurrency to power the economics on the BitTorrent network. The Token will be used to inceltivize file sharing and storage within the network.

Tron

Tron is trending as the community discusses its position as a settlement layer for stablecoins and its growing ties to Rumble. Community members are also weighing the potential impact of Keeta, a compliance-focused protocol, on Tron's future, with some viewing it as a complement rather than a competitor. Recent discussions highlight Tron's established role in USDT transfers and its potential for further integration with real-world payment systems.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is trending due to positive sentiment around its strong growth in the AI infrastructure space and potential for continued gains. The community is discussing the company's impressive revenue growth and strategic partnerships, especially given its focus on high-speed connectivity solutions. However, some are cautious about the stock's high valuation and potential for a pullback, while others believe it has significant long-term potential.

Victoria's Secret & Co. operates as a lingerie, clothing and beauty retailer. It offers bras, panties, lingerie, pajamas, sleep, sport and swim apparel, and beauty products. The company was founded in 1963 and is headquartered in Reynoldsburg, OH.

Victoria`s Secret & Co

Victoria's Secret & Co. is trending as the company reported earnings, with community members actively discussing whether it got ahead of itself prior to the report. Despite mixed analyst ratings and price target adjustments, insider buying and takeover speculation are also fueling interest in the stock. The holiday season and potential tariff reductions add further context to the conversation around $VSCO.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Galectin Therapeutics is trending as the community discusses its potential for accelerated FDA approval and a possible buyout following recent presentations; positive biomarker data and a clean safety profile are fueling optimism. Chatter around trading restrictions on some platforms has sparked speculation about manipulation and an impending short squeeze. Many are closely monitoring the company for further news regarding FDA feedback and strategic partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Bloomberg reported that the Centers for Medicare &amp; Medicaid Services (CMS), which runs the Medicare program, is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;</li><li>MSOS and YOLO, two key cannabis sector-focused funds, gained 3.4% and 2.7%, respectively.</li><li>The Trump administration seems to be backing cannabis as an industry, following its previous comments regarding CBD and reclassifying marijuana.</li></ul>Cannabis&nbsp;stocks advanced on Wednesday following a report speculating that certain U.S Medicare patients could soon be eligible to receive coverage for CBD under a new initiative.CBD, or cannabidiol, is a compound found in cannabis and used to treat sleep disorders, anxiety, pain, and inflammation. Some research suggests it may also treat cancer symptoms. The drug is sold as gummies, pet treats, and skincare supplements.<h2 class="st-heading-2">Cannabis Stocks Rally</h2>Tilray Brands’ shares rose 4.8%, while the over-the-counter stocks of Curaleaf Holdings, Trulieve Cannabis, and Green Thumb Industries gained between 2% to 5.6%. Shares of Innovative Industrial Properties, a real estate investment trust (REIT) that buys and leases specialized cannabis cultivation facilities, rose 1.1%.On Stocktwits, the retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/TLRY">TLRY</a> shifted to ‘extremely bullish’ from ‘bullish,’ while that for&nbsp;<a href="https://stocktwits.com/symbol/CURLF">CURLF</a> shifted to ‘bullish’ from ‘neutral.’ The sentiment was ‘bullish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">GTBIF</a>, and ‘bearish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">TCNNF</a> and&nbsp;<a href="https://stocktwits.com/symbol/IIPR">IIPR</a> as of the last reading.&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF (MSOS)</a>, which tracks U.S. cannabis companies exclusively, and the&nbsp;<a href="https://stocktwits.com/symbol/YOLO">AdvisorShares Pure Cannabis ETF (YOLO)</a>, which also tracks overseas companies and cannabis-adjacent businesses, rose 3.4% and 2.7%, respectively.<h2 class="st-heading-2">CMS Initaitive</h2>The rally came after Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-26/medicare-to-test-making-cbd-treatment-available-for-seniors">reported</a> that the Centers for Medicare &amp; Medicaid Services (CMS) is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;Details of the proposed program aren’t available, but an early version of the plan focused on seniors in oncology and palliative care settings, according to a summary viewed by the news agency.Unnamed sources told Bloomberg that Howard Kessler, a payments financier who has advocated for expanded CBD access, met with Health and Human Services Secretary Robert F. Kennedy Jr. about the issue last month<h2 class="st-heading-2">A Trump Boost?</h2>The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. Hemp-derived cannabidiol (CBD) could "revolutionize senior healthcare" by slowing disease progression and serving as an alternative to prescription drugs, Trump had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-cannabis-stocks-lose-high-premarket-after-surge-triggered-by-trumps-post/chDDTJ9R3BB">said</a> in a video post in September.The previous month, Trump said his administration was weighing a move to reclassify marijuana as a less dangerous drug under federal law.That said, doubts over cannabis efficacy in healthcare remain. A&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836267">recent study</a> funded by the Food and Drug Administration suggested that prolonged use of CBD may cause liver toxicity, while other research suggests it can interfere with other medications, harm male reproductive health, and pose potential risks to children and pregnant women.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/holiday-shopping-could-soar-to-a-record-1-trillion-this-year-with-online-spending-blasting-to-new-highs/cL5eLqVREW6">Holiday Shopping Could Soar To A Record $1 Trillion This Year, With Online Spending Blasting To New Highs</a>

Cannabis plants grow in the greenhouse at Vireo Health's medical marijuana cultivation facility, August 19, 2016 in Johnstown, New York. (Photo by Drew Angerer/Getty Images)

Tilray, IIPR, Trulieve, Other Cannabis Stocks Rally On Report Of Government Considering Adding CBD Treatment For Medicare Patients  

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. 

Equity

Stocks of cannabis sellers Tilray Brands Inc. and Canopy Growth Corp.&nbsp;fell 5% and 1.3%, respectively, in the early premarket session on Tuesday.Weed stocks&nbsp;seem to be losing momentum from the previous day, when the sector rallied following President Donald Trump's post highlighting the potential benefits of using cannabidiol in senior healthcare.Hemp-derived cannabidiol (CBD) could "revolutionize senior healthcare" by slowing disease progression and serving as an alternative to prescription drugs, Trump said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/115283887618990920">video post</a> on Truth Social on Sunday.Major companies&nbsp;<a href="https://stocktwits.com/symbol/CURLF">Curaleaf Holdings</a>,&nbsp;<a href="https://stocktwits.com/symbol/TCNNF">Trulieve Cannabis</a>, and&nbsp;<a href="https://stocktwits.com/symbol/GLASF">Glass House Brands</a> rose 37% to 21% on Monday. They have over-the-counter (OTC) shares listed in the U.S., which do not trade pre- and after-market.<a href="https://stocktwits.com/symbol/TLRY">Tilray shares</a> gained 60% hitting a 52-week high, while&nbsp;<a href="https://stocktwits.com/symbol/CGC">Canopy stock</a> ended 17% higher.On Stocktwits, the retail sentiment was 'extremely bullish' for Tilray, 'bullish' for Curaleaf, Canopy, and Trulieve, and 'bearish' for Glass House, as of early Tuesday.A bullish user projected strong gains in the stocks should a formal announcement regarding the CBD be made.<stembedurl>https://stocktwits.com/angelfromsky/message/630185575</stembedurl>Trump said last month that his administration was weighing a reclassification of marijuana. The potential move would classify marijuana as less dangerous under federal law and could lead to easing criminal penalties tied to its use.Meanwhile, regulations around the commercial use of hemp and CBD were significantly eased through the Agriculture Improvement Act, enacted during Trump's first term. As of now, marijuana remains listed as a Schedule I substance under the Controlled Substances Act, meaning it has a high potential for abuse and no current accepted medical use.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dozens of varieties of marijuana samples are on display at a dispensary in New York. (Photo by John Paraskevas/Newsday RM via Getty Images)

Tilray, Canopy Growth: Cannabis Stocks Lose High Premarket After Surge Triggered By Trump's Post

Major weed stocks rallied the previous day after President Donald Trump's post, which highlighted the potential benefits of using cannabidiol in senior healthcare.

President Donald Trump confirmed on Monday that he is looking at reclassifying marijuana and may announce his final decision in the next few weeks. "We're looking at reclassification, and we'll make a determination over the next few weeks," Trump told reporters during a press conference about cracking down on crime in Washington, D.C.His comments come after The Wall Street Journal (WSJ)&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/politics/policy/trump-marijuana-federal-drug-classification-01a73b8c">reported</a> last week that Trump may be interested in changing the drug’s classification. Marijuana-linked stocks like Aurora Cannabis (ACB), Canopy Growth (CGC), Tilray Brands (TLRY), Cronos Group (CRON), and Trulieve Cannabis (TCNNF) were already rallying in pre-market trade on the report.&nbsp;They continued to rally after Trump’s confirmation, with&nbsp;<a href="http://stocktwits.com/symbol/CGC">Canopy Growth’s</a> stock surging nearly 30% in midday trade.&nbsp;<a href="http://stocktwits.com/symbol/TLRY">Tilray’s stock</a> jumped 22%, followed by&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="http://tcnnf">Trulieve’s stock</a> gaining more than 18%. Aurora Cannabis’s stock climbed 12.5% on Monday.On Stocktwits, retail sentiment around Canopy Growth moved higher within ‘extremely bullish’ territory amid ‘extremely high’ levels of chatter. Meanwhile, retail sentiment around Tilray Brands improved to ‘bullish’ from ‘bearish’ a day ago, and retail sentiment around Trulieve was moved higher within ‘extremely bullish’ territory.“Some people like it. Some people hate it. Some people hate the whole concept of marijuana, because if it’s bad for the children, it’s bad for people older than children,” the President said, noting that medical marijuana, specifically, may hold benefits.&nbsp;“I’ve heard great things to do with medical, and I’ve heard bad things having to do with just about everything else but medical,” he said.Reclassification of marijuana from a Schedule I drug to a Schedule III drug would ease restrictions, allow tax breaks, and expand medical research.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-declares-liberation-day-in-dc-pushes-takeover-of-city-police/chrHGOoRdee">Trump Declares ‘Liberation Day’ in DC, Pushes Takeover Of City Police</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions during a press conference in the James S. Brady Press Briefing Room of the White House August 11, 2025 in Washington, DC. (Photo by Andrew Harnik/Getty Images)

Trump Confirms Marijuana Reclassification Decision To Be Made In ‘Next Few Weeks’ 

The President noted that there’s a difference of opinion on the benefits of marijuana, but added that he’s heard “great things” with respect to medical marijuana, specifically.

Retail sentiment picked up Sunday for Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON) and Trulieve Cannabis (TCNNF) after reports that U.S. President Donald Trump may reclassify marijuana as a less dangerous drug.&nbsp;The Wall Street Journal&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/politics/policy/trump-marijuana-federal-drug-classification-01a73b8c">said</a> that at a $1 million-a-plate fundraiser at his New Jersey golf club earlier this month, Trump told guests he was interested in the change, signaling an effort the Biden administration had started but never completed.Reclassification to Schedule III would ease restrictions, allow tax breaks, and expand medical research. Trulieve CEO Kim Rivers reportedly urged Trump to pursue the shift and expand research. Trump flagged the idea to staff. Other guests included Pfizer’s CEO, cryptocurrency executives, and political advisers.Cannabis companies have contributed millions to Trump’s political groups, hired lobbyists close to him, and backed American Rights and Reform PAC, which gave $1 million to Trump’s PAC and commissioned polling from Trump pollster Tony Fabrizio showing Republican and independent voter support.The PAC also paid $300,000 to Trump adviser Alex Bruesewitz for social media and advertising work.Bruesewitz said, “This is not calling for decriminalization or legalization but simply knocking it down a few notches on the criminal scale.”Trump said last year he would vote for legalization in Florida after meeting with Trulieve and lobbyist Brian Ballard. Senior officials said he does not personally support marijuana but is interested in “80-20 cultural issues” with broad backing and has referenced friends who used medical marijuana.Opposition groups include Smart Approaches to Marijuana, which has run ads on Fox programs, and the Community Anti-Drug Coalitions of America, which urged members to contact the White House.White House spokeswoman Abigail Jackson said, “All policy and legal requirements and implications are being considered. The only interest guiding the president’s policy decisions is what is in the best interest of the American people.”On Stocktwits, retail sentiment was “extremely bullish” with “high” message volume for ACB, CGC, and TCNNF, while CRON was “bullish” with “high” message volume.One user noted that cannabis company stocks jumped between 30% and 40% after multiple reports in April 2024 that marijuana would be reclassified to a less dangerous drug schedule.<stembedurl>https://stocktwits.com/Icarus81/message/624511957</stembedurl>Another user pointed out that the last time there was similar regulatory talk, ACB rose sharply to more than $8 a share, and said it should be “an interesting week to say the least.”<stembedurl>https://stocktwits.com/LionsFan/message/624533180</stembedurl>So far this year, ACB is up 5.4%, CGC is down 54.4%, CRON is up 13.9% and TCNNF is up 10.5%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

So far this year, ACB is up 5.4%, CGC is down 54.4%, CRON is up 13.9% and TCNNF is up 10.5%. (Photo credit: Getty Images)

Retail Bulls Pile Into Cannabis Stocks On Reports Trump May Reclassify Marijuana; Traders Eye Aurora Rally

Cannabis firms have spent millions lobbying Trump to shift marijuana to Schedule III, easing restrictions and enabling tax breaks.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products and services. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Quincy, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

$CRWD

$CRM

$SNOW

$MDB

Which earnings report are you most looking forward to this week? 
 
Drop a comment for others.

TCNNF
Trulieve Cannabis

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TCNNF News

TCNNFTrulieve Cannabis